In preclinical prostate carcinoma in the bone, Rad-223 eradicated effectively micro-tumors but macro-tumors persisted and expanded. The data point to application of Rad-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the tumor core.Peter Friedl, theme Cancer development and immune defense, and colleagues, published these findings in the Journal of the National Cancer Institute (JNCI).
Bone-targeting radiotherapy with Radium-223 (Rad-223), a radioisotope emitting genotoxic alpha-radiation with limited tissue penetrance (∼100 µm), prolongs the survival of patients with metastatic prostate cancer (PCa). Confoundingly, the clinical response to Rad-223 is often followed by detrimental relapse and progression, and whether Radium-223 causes tumor-cell directed cytotoxicity in vivo remains unclear. In a joint effort between the Radboudumc and the MD Anderson Cancer Center, they show that limited radiation penetrance in situ defines outcome.
They tested the Radium-223 overall response in prostace cancer in mouse bones and applied intravital microscopy and in silico modeling to predict Rad-223 effectiveness in lesions of different sizes. Rad-223 caused profound cancer cell lethality along the bone interface but not the more distant tumor core. In silico simulations predicted greater efficacy of Rad-223 on single-cell lesions (eradication rate: 88.0%) and minimal effects on larger tumors (no eradication, 16.2% growth reduction in tumors of 27,306 cells), further confirmed in vivo tumors in mice. Micro-tumors showed severe growth delay or eradication in response to Rad-223, whereas macro-tumors persisted and expanded.
The relative inefficacy in controlling large tumors points to application of Rad-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the bone niche together with the tumor core.
Related news items
A personal touch of Jaap ten Oever20 June 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Jaap ten Oever.read more
Radboudumc Master Prize for Mark van Goor18 June 2019
Mark van Goor, theme Renal disorders, received the Radboudumc Master Prize for his MSc thesis entitled “High-resolution structure of the renal calcium channel TRPV5 revealed with cryo-EM”, which was based on his internship at the lab of Prof. Yifan Cheng, USA.read more
Pathogenic fungus can make artificial leather waterproof18 June 2019
Paul Verweij and Sybren de Hoog, theme Infectious diseases and global health, won the Bio Art & Design Award to further develop the development of waterproof synthetic leather.read more
A warm welcome for Hypatia fellow Daniele Tauriello18 June 2019
It is our pleasure to welcome a new research group leader and Hypatia fellow at RIMLS: Daniele Tauriello (dept Cell Biology).read more
Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies18 June 2019
Exome sequencing may provide a genetic diagnosis in a significant number of patients in a single genetic test. Alexander Hoischen and Mihai Netea, theme Infectious diseases and global health, and colleagues, published their results in Genome Medicine.read more
Lowering cholesterol is not enough to reduce hyperactivity of the immune system14 June 2019
In Cell Metabolism, Siroon Bekkering, theme Vascular damage, and colleagues, provide a novel potential explanation for the residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.read more